ArticleJournal of intensive care2026
Impact of an ROX index-guided intubation strategy on mortality in patients receiving high-flow nasal cannula: a target trial emulation.
Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ROX index (the ratio of peripheral oxygen saturation to the fraction of inspired oxygen, divided by respiratory rate) has been validated to predict high-flow nasal cannula (HFNC) failure, but whether acting on ROX to guide the timing of intubation improves patient outcomes is unknown. We estimated the per-protocol effect of ROX-guided strategies versus usual care on mortality after HFNC initiation.
methodsWe emulated target trials using Medical Information Mart for Intensive Care IV (MIMIC-IV) electronic health record data. Adults initiated on HFNC within 7 days of intensive care unit (ICU) admission were eligible. Strategies were usual care or intubation within 2 h after ROX first fell below 3.85, 4.88, or time-varying thresholds (2.85 for hours 1-5, 3.47 for hours 6-11, and 3.85 from hour 12). We used clone-censor-weighting with pooled logistic regression, adjusted for baseline and time-varying covariates, to estimate 30-day mortality.
resultsWe included 1,651 adults (median age, 66 years; women, 41%). Estimated 30-day mortality under usual care was 26.9% (95% CI 24.7-29.2). ROX < 3.85: 20.5% (95% CI 17.1-24.1; risk difference [RD], -6.5 percentage points [95% CI -9.1 to -3.8]; risk ratio [RR], 0.76 [95% CI 0.66-0.86]). ROX < 4.88: 19.8% (95% CI 16.3-24.0; RD, -7.1 percentage points [95% CI -10.3 to -3.5]; RR, 0.74 [95% CI 0.62-0.87]). Time-varying ROX: 21.3% (95% CI 18.5-24.3; RD, -5.6 percentage points [95% CI -7.9 to -3.4]; RR, 0.79 [95% CI 0.70-0.87]).
conclusionsROX-guided intubation strategies were associated with lower 30-day mortality than usual care. These findings are hypothesis-generating and support prospective evaluation of the ROX index applied as a decision policy rather than as a prediction score alone; they should not be used to guide intubation decisions at present.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.